Spinocerebellar Ataxia Type 3 Clinical Trial
— PRIME-AtaxiaOfficial title:
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia: a Randomized Controlled Trial (PRIME-Ataxia RCT)
Verified date | May 2024 |
Source | Teachers College, Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
PRIME-Ataxia is a randomized controlled trial that aims to determine the feasibility and efficacy of an 8-week telehealth intervention of high intensity aerobic exercise prior to balance training compared to an 8-week telehealth intervention of low intensity exercise prior to balance training in people with spinocerebellar ataxias (SCAs). The investigators additionally aim to explore changes in motor skill learning on a novel motor skill task in a sub-group of participants pre and post intervention.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | May 31, 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Between the ages of 18 to 85 years 2. Genetically confirmed diagnosis of SCA1, 2, 3, 6, and 7 3. Scale for Ataxia Rating and Assessment (SARA) score between 8-25/40, capturing mild-moderate disease 4. Able to walk with/without assistive device 5. Successful completion of Physical Activity Readiness Questionnaire (PAR-Q) to confirm no medical contraindications to exercise 6. Care partner availability during assessments and/or intervention pending balance scores Exclusion Criteria: 1. Severe non-ataxic motor symptoms such as dystonia, tremor, or Parkinsonism, measured by Inventory of Non-Ataxia Signs (INAS) 2. Peripheral sensory loss (as confirmed with monofilament or clinical proprioceptive testing) 3. Severe visual complications associated with ataxia (i.e., Spontaneous nystagmus, retinal or optic nerve involvement, especially in SCA7) defined as as have a score on the Snellen Visual Acuity test = 20/200 - 20/400, OR a visual field of 20 degrees of less. 4. Musculoskeletal injury that would prevent participation in an exercise program 5. Other concurrent disease of the cerebellum (e.g. stroke, multiple sclerosis) 6. Cardiac/pulmonary conditions that would affect participants ability to participate exercise program 7. Currently engaged in >3 week moderate-high intensity aerobic exercise and/or balance training |
Country | Name | City | State |
---|---|---|---|
United States | Teachers College, Columbia University | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Teachers College, Columbia University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Scale for Assessment and Rating for Ataxia | Clinical rating scale for severity of ataxia symptoms. This is an 8-item clinical performance based scale, which individuals are graded according to total ataxia severity. Total scores can range from 0 (no ataxia) to 40 (most severe ataxia). Scores are based on performance of the following tasks: 1) Gait, 2) Stance, 3), Sitting, 4) Speech Disturbance, 5) Finger Chase, 6) Nose-Finger Test, 7) Fast alternating hand movements, 8) Heel-shin slide. For the purpose of this study, we will be performing a validated modified version of the SARA, referred to as the SARAHome. The SARAHome is comprised of the first four items and item 6 from the original SARA Scale (Gait, Stance, Walking, Speech, and Nose-Finger Test) and it will be administered via telehealth. | Baseline, Post-Intervention (4 months) | |
Primary | Change in Cerebellar Cognitive Affective Syndrome Scale | The Cerebellar Cognitive Affective Syndrome Scale (CCAS) was developed as a bedside quick screen for Cerebellar Cognitive Affective Symptom (also referred to as Schmalmann's Syndrome). The CCAS is a 10-item scale of cognitive and neuropsychiatric tests detailing executive function, working and verbal memory, language, visuospatial function, abstract reasoning, behavior and affect. Two scores are reported; a raw score ranging from 0 (severe cognitive impairment) to 120 points (no cognitive impairment), as well as a Pass/Fail marker for each of the 10 items on the scale. 1 fail is considered as possible cerebellar cognitive affective symptom, 2 fails are considered probable, and 3 fails are considered clinically definite. | Baseline, Post-Intervention (4 months) | |
Primary | Change in Patient Reported Outcome Measure for Ataxia | Patient reported outcome measure for people with ataxia. The test was developed to assess 3 domains (physical, activities of daily living, mental health) and 14 subdomains. It has been proven to be valid and reliable against measures of motor ataxia, mental health, and quality of life. The original Patient Reported Outcome Measure for Ataxia has 70 questions, and records a total score out of 280 possible points. For the purpose of this trial, we will use the Short-Form version of this assessment which asks 10 questions, and it scored out of a total of 40 possible points. | Baseline, Post-Intervention (4 months) | |
Secondary | Activities Specific Balance Scale (ABC) | Patient reported outcome evaluating the balance confidence of a participant in performing a variety of activities without losing balance or experiencing a state of unsteadiness. Participants are asked to rank their perceived balance confidence on a scale of 0% (no balance confidence) to 100% (high balance confidence). All scores are summed, and averaged for a total overall estimate of balance confidence. | Baseline, Post-Intervention (4 months) | |
Secondary | Digital Biomarker of Static Posturography | Participant will perform a series of static standing postures and postural sway will be recorded with a smart phone app, and/or inertial measurement units. Measure of postural sway will be recorded (higher values are worse outcomes). | Baseline, Post-Intervention (4 months) | |
Secondary | Digital Biomarker of Dynamic Posturography | Participant will perform a walking test which will be recorded with a smart phone app, and/or inertial measurement units. Measure of postural sway will be recorded (higher values are worse outcomes). | Baseline, Post-Intervention (4 months) | |
Secondary | Motor Adaptation | Prism Adaptation with finger targeting to touchscreen. Performed in a sub-set of participants for this trial. | Baseline, Post-Intervention (4 months) | |
Secondary | Neurological Quality of Life | Self report of health related quality of life for people with neurological conditions. The measure that will be used in this trial is a short-form assessing social or functional roles and abilities. 8 questions with 5-item Likert response, higher score is better outcome. | Baseline, Post-Intervention (4 months) | |
Secondary | Patient Global Impression of Change | Self-report measure that assesses a participants thoughts or beliefs about the efficacy of treatment. The Patient Global Impression of Change scale is a 7 point scale depicting a patient's rating of overall improvement, score 1-7, higher score is better. | Baseline, Post-Intervention (4 months) | |
Secondary | Acceptability Questionnaire | Short open-ended questionnaire to assess the acceptability of the intervention. These open-ended questions will be analyzed qualitatively. | Baseline, Post-Intervention (4 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00992771 -
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Completed |
NCT01096082 -
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03701399 -
Troriluzole in Adult Subjects With Spinocerebellar Ataxia
|
Phase 3 | |
Active, not recruiting |
NCT04229823 -
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
|
||
Active, not recruiting |
NCT04419974 -
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
|
||
Terminated |
NCT05490563 -
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04301284 -
Study of CAD-1883 for Spinocerebellar Ataxia
|
Phase 2 | |
Withdrawn |
NCT01096095 -
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
|
Phase 2 | |
Active, not recruiting |
NCT04268147 -
Instrumented Data Exchange for Ataxia Study
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Recruiting |
NCT04399265 -
Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
|
N/A | |
Completed |
NCT03885167 -
Identification of Biomarkers in Spinocerebellar Ataxia 3
|
||
Terminated |
NCT05160558 -
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
|
Phase 1 | |
Recruiting |
NCT05822908 -
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03378414 -
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
|
Phase 2 | |
Completed |
NCT05502432 -
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
|
N/A | |
Recruiting |
NCT04714307 -
Neuropsychiatry and Cognition in SCA3/MJD
|
||
Recruiting |
NCT05557786 -
Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
|
||
Recruiting |
NCT01060371 -
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
|